[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338452-105":59,"doc-detail-338452-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","integrating-immunotherapy-with-conventional-treatment-regime-for-breast-cancer-patients-an-amalgamation-of-armamentarium","Integrating immunotherapy with conventional treatment regime for breast cancer patients - an amalgamation of armamentarium","","Immunotherapy is presented as a leading strategy aimed at achieving efficient remission across cancer types, with immune checkpoint inhibitors (ICIs) generating growing interest for breast cancer. Molecular heterogeneity in breast cancer limits the effectiveness of many treatment regimens, while clinical trials show benefit in selected subtypes. Because ICI monotherapy is not sufficient for all patients, the review evaluates how ICIs interact with established and emerging anticancer therapies. It also assesses immune-cell modulation for improved response, summarizes ongoing clinical-trial evidence combining immunotherapy with conventional modalities, and highlights microbiota modulation as a key regulator with potential applications in breast cancer.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/integrating-immunotherapy-with-conventional-treatment-regime-for-breast-cancer-patients-an-amalgamation-of-armamentarium/338452/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/integrating-immunotherapy-with-conventional-treatment-regime-for-breast-cancer-patients-an-amalgamation-of-armamentarium/338452.png","ImageObject",300,407,{"name":92,"@type":93},"Seraphina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is immunotherapy particularly relevant to breast cancer patients?","Question",{"text":112,"@type":113},"Immunotherapy, especially immune checkpoint inhibitors, has shown promising therapeutic directions across cancer types, and research interest is expanding specifically for breast cancer. The review frames ICIs as a key focus due to their potential impact on breast cancer outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What makes breast cancer challenging for treatment effectiveness?",{"text":117,"@type":113},"Breast cancer is characterized by molecular heterogeneity, which restricts the efficacy of many therapeutic regimens. This heterogeneity leads to substantial variation in treatment choice and therapeutic response among patients.",{"name":119,"@type":110,"acceptedAnswer":120},"Why are combinatorial approaches emphasized over ICI monotherapy?",{"text":121,"@type":113},"The review notes that ICI monotherapy may be insufficient for all breast cancer patients. It therefore highlights the need to understand and optimize combinations of ICIs with conventional and novel anticancer regimens.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338452,1790102388,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","TYPE Review  \nPUBLISHED 01 November 2024 DOI 10.3389/fimmu.2024.1477980  \nOPEN ACCESS  \nEDITED BY  \nMohd Wajid Ali Khan,  \nUniversity of Hail, Saudi Arabia  \nREVIEWED BY  \nMansoor-Ali Vaali-Mohammed, King Saud University, Saudi Arabia Wahid Ali Khan,  \nKing Khalid University, Saudi Arabia  \n*CORRESPONDENCE  \nDipali Sharma  \n [dsharma7@jhmi.edu](dsharma7@jhmi.edu)[ ](dsharma7@jhmi.edu)Deeptashree Nandi  \n [dnandi1@jhmi.edu](dnandi1@jhmi.edu)  \nRECEIVED 08 August 2024  \nACCEPTED 08 October 2024  \nPUBLISHED 01 November 2024  \nCITATION  \nNandi D and Sharma D (2024) Integrating immunotherapy with conventional treatment regime for breast cancer patients-an amalgamation of armamentarium.  \nFront. Immunol. 15:1477980 .  \ndoi: 10.3389/fimmu.2024.1477980  \nCOPYRIGHT  \n© 2024 Nandi and Sharma. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nIntegrating immunotherapy with conventional treatment regime for breast cancer patients-an amalgamation of armamentarium  \nDeeptashree Nandi* and Dipali Sharma*  \nDepartment of Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States  \nImmunotherapy stands as the frontrunner in treatment strategies imparting efﬁcient remission in various types of cancer. In fact, emerging breakthroughs with immune checkpoint inhibitors (ICI) in a spectrum of cancers have evoked interest in research related to the potential effects of immunotherapy in breast cancer patients. A major challenge with breast cancer is the molecular heterogeneity that limits the efﬁcacy of many therapeutic regimes. Clinical trials have shown favorable clinical outcomes with immunotherapeutic options in some subtypes of breast cancer. However, ICI monotherapy may not besufﬁcient for all breast cancer patients, emphasizing the need for combinatorial approaches. Ongoing research is focused on untangling the interplay of ICI with established as well as novel anticancer therapeutic regimens in preclinical models of breast cancer . Our review will analyze the existing research regarding the mechanisms and clinical impact of immunotherapy for the treatment of breast cancer . We shall evaluate the role of immune cell modulation for improved therapeutic response in breast cancer patients. This review will provide collated evidences about the current clinical trials that are testing out the implications of immunotherapy in conjunction with traditional treatment modalities in breast cancer and summarize the potential future research directions in the ﬁeld. In addition, we shall underline the recent ﬁndings related to microbiota modulation as a key regulator of immune therapy response in cancer patients and its plausible applications in breast cancer.  \nKEYWORDS  \nimmunotherapy, breast cancer, triple-negative breast cancer, combination therapy, treatment  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \n1 Introduction  \nBreast cancer persists as a global health menace, accounting for one-third of all new cancer cases and ranking as the second most prevalent malignancy among women (1) . With more than 2.3 million cases worldwide, breast cancer incidence is currently on the rise. Depending on the type of hormone receptors being expressed on the breast carcinoma cells, there exist four primary molecular subtypes of breast cancer; estrogen receptor/progesterone receptor (ER/PR)-positive but HER2-negative (luminal A) that comprises of more than half of the breast cancer cases; ER/HER2-positive but PR-negative (luminal B) -hormone therapy as well as chemother","cbCaibCdjlGFFFvE","https://ap.wps.com/l/cbCaibCdjlGFFFvE","pdf",962912,17,"English","# Introduction\n## Breast cancer subtypes and treatment landscape","[{\"question\":\"Why is immunotherapy particularly relevant to breast cancer patients?\",\"answer\":\"Immunotherapy, especially immune checkpoint inhibitors, has shown promising therapeutic directions across cancer types, and research interest is expanding specifically for breast cancer. The review frames ICIs as a key focus due to their potential impact on breast cancer outcomes.\"},{\"question\":\"What makes breast cancer challenging for treatment effectiveness?\",\"answer\":\"Breast cancer is characterized by molecular heterogeneity, which restricts the efficacy of many therapeutic regimens. This heterogeneity leads to substantial variation in treatment choice and therapeutic response among patients.\"},{\"question\":\"Why are combinatorial approaches emphasized over ICI monotherapy?\",\"answer\":\"The review notes that ICI monotherapy may be insufficient for all breast cancer patients. It therefore highlights the need to understand and optimize combinations of ICIs with conventional and novel anticancer regimens.\"}]","Integrating immunotherapy with conventional treatment regime for breast cancer patients - an amalgamation of armamentarium | PDF",1790023686,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0314580946aeac8a07a4acee5b60b831.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4b70d9309cb771280d2f63d4b8eb3cbf.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b5c09a8797157911b668d4f0db373203.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ca5dd0b50e575a90eb450249acb03ed4.webp",980,1385]